India's pharma leap: policy, innovation & global leadership

India’s role in global healthcare, often celebrated with the title ‘Pharmacy of the World,’ stands at a pivotal juncture. While its dominance in generic drug manufacturing has been a cornerstone of global health equity, the nation is now embarking on an ambitious transformation. Driven by new, forward-looking policies enacted in 2023, the focus is shifting from high-volume production to high-value innovation, aiming to secure a leadership position in research, development, and next-generation medical technology.

Historically, India’s medical knowledge has deep roots, with ancient texts like the Sushruta Samhita demonstrating sophisticated surgical techniques centuries ago. Today, this legacy is evolving. The modern Indian pharmaceutical industry, which began to flourish after the patent reforms of the 1970s, is now the third-largest in the world by volume.

Fun Fact: India is one of the largest vaccine manufacturers in the world, supplying over 60% of the global demand for various vaccines, including those for Diphtheria, Tetanus, and Pertussis (DTP), and Bacillus Calmette-Guérin (BCG).

The New Policy Thrust: From Volume to Value

The Government of India has recognized that the next phase of growth must be innovation-led. To catalyze this shift, several landmark policies were introduced recently, fundamentally reshaping the R&D and manufacturing landscape.

1. Promotion of Research & Innovation in Pharma-MedTech (PRIP) Scheme (2023)

The PRIP scheme, with a significant corpus of ₹5,000 crore (approx. $600 million) for the period from FY 2023-24 to FY 2027-28, is the government’s flagship initiative to correct the long-standing R&D deficit. Its primary goal is to transition the pharmaceutical sector from cost-based competitiveness to one driven by value and innovation.

The scheme is built on two key components:

• Component A: Establishing seven Centres of Excellence (CoEs) in various NIPERs (National Institutes of Pharmaceutical Education and Research) to build advanced research infrastructure.
• Component B: Providing direct financial assistance to private companies (SMEs and large firms) for research projects across six priority areas, including new chemical entities, complex generics, and AI-based drug discovery.

Mnemonic for PRIP Priority Areas: Remember the key research focuses with “DR. BIO-AI”

• Drug Discovery
• RNA therapeutics
• BIOpharmaceuticals
• AI in drug discovery
• In-vitro diagnostic devices

2. National Medical Devices Policy, 2023

Approved in April 2023, this policy aims to accelerate growth in the medical devices sector, with a vision to make India a global leader. It seeks to increase the industry’s market size from an estimated $11 billion to $50 billion by 2030.

Analogy: Think of the Indian pharma industry as a master chef famous for perfectly recreating classic recipes (generics). The new policies are like building a state-of-the-art culinary lab (R&D infra) and funding a competition (PRIP scheme) to invent entirely new dishes (novel drugs).

Critical Policy Appraisal

While recent initiatives are promising, the path to becoming an innovation hub has both opportunities and significant hurdles.

Statistic: The Indian pharmaceutical market is expected to reach $130 billion in value by 2030, growing from approximately $50 billion in 2023, showcasing immense growth potential.

Analytical Lens: UPSC Focus (Mains & Prelims)

Conceptual Basis: The foundational legal framework governing the quality, manufacturing, and import of drugs and medical devices in India is the Drugs and Cosmetics Act, 1940, and its subsequent rules. The Central Drugs Standard Control Organization (CDSCO) is the national regulatory body responsible for its enforcement.

UPSC Integration: Connecting the Dots

• GS Paper 2 (Polity & Governance, Social Justice): Health is a State Subject, but drug regulation is on the Union List. This creates federal complexities. The topic is central to ‘Government Policies and Interventions’ and ‘Issues Relating to Health’.
• GS Paper 3 (Economy, Science & Tech): The pharmaceutical industry is a key component of India’s manufacturing sector, export earnings, and GDP. It directly relates to ‘Industrial Policy’, ‘Investment Models’, and ‘Achievements of Indians in S&T’.
• GS Paper 2 (International Relations): India’s role as the ‘Pharmacy of the World’ is a major element of its soft power and foreign policy, particularly in its relationship with the Global South (e.g., Vaccine Maitri initiative).

Expert Analysis: The Long-Term Horizon The current policy momentum signals a crucial inflection point. The long-term success of India’s pharmaceutical sector will depend on its ability to transition from a high-volume, low-cost manufacturer to a high-value, innovation-driven leader. The PRIP and National Medical Devices Policy, 2023, are not just industrial policies; they are strategic geopolitical assets. By building a self-reliant R&D ecosystem, India can reduce its dependency on China for APIs, enhance its credibility as a reliable global supplier, and capture a larger share of the profitable patented drug market. The future impact hinges on effective implementation, sustained funding, and fostering a culture of deep-science research that bridges the gap between academia and industry.

Prelims Practice Question (MCQ):

Which of the following is the primary national regulatory body in India responsible for the approval of new drugs and the conduct of clinical trials? a) Indian Council of Medical Research (ICMR) b) National Pharmaceutical Pricing Authority (NPPA) c) Central Drugs Standard Control Organization (CDSCO) d) Department of Pharmaceuticals

Answer and Explanation: c) Central Drugs Standard Control Organization (CDSCO): The CDSCO, under the Directorate General of Health Services, Ministry of Health & Family Welfare, is the National Regulatory Authority (NRA) of India. Its primary functions include drug approval, conduct of clinical trials, laying down drug standards, and quality control over imported drugs. The ICMR is a biomedical research body, the NPPA controls drug prices, and the Department of Pharmaceuticals is a policy-making body.

Mains Sample Question:

“While India is celebrated as the ‘Pharmacy of the World,’ it faces significant challenges in moving up the value chain from generic manufacturing to drug innovation. Critically analyze the recent government initiatives, like the PRIP scheme, aimed at fostering R&D and suggest measures to ensure their effective implementation.” (15 Marks, 250 Words)

Mind Map Outline (Revision Structure)

• India’s Pharmaceutical Sector: An Overview
  • Core Identity: ‘Pharmacy of the World’
  • Historical Context:
    • Ancient Roots: Sushruta Samhita
    • Modern Industry: Post-1970s patent laws
  • Current Status:
    • 3rd largest by volume
    • Largest supplier of generic drugs (20% global share)
    • Major vaccine manufacturer (60% global supply)
• Strategic Policy Shift: Volume to Value
  • Promotion of Research & Innovation in Pharma-MedTech (PRIP) Scheme (2023)
    • Objective: Shift from cost-based to value-driven industry.
    • Corpus: ₹5,000 crore (2023-2028).
    • Components:
      • Component A: Centres of Excellence (CoEs) in NIPERs.
      • Component B: Financial aid to private firms for R&D.
  • National Medical Devices Policy (2023)
    • Vision: Make India a global MedTech leader.
    • Target: $50 billion industry by 2030.
    • Pillars: Regulation, Infrastructure, R&D, Investment, HRD.
• Critical Appraisal of the Sector
  • Challenges & Criticisms:
    • API Dependency on China
    • Low R&D Spending (<1% of GDP)
    • Regulatory & Quality Control Issues
  • Opportunities & Strengths:
    • Success of PLI Scheme for APIs
    • ‘China Plus One’ global strategy
    • Established reputation (Vaccine Maitri)
    • Large and growing domestic market
• UPSC Analytical Framework
  • Legal Backbone: Drugs and Cosmetics Act, 1940 & CDSCO.
  • Inter-Topic Linkages:
    • Polity (Federalism, Health Policy)
    • Economy (GDP, Exports, PLI Scheme)
    • International Relations (Soft Power, Vaccine Maitri)
  • Practice Questions:
    • Prelims MCQ on CDSCO.
    • Mains Question on R&D challenges and policy effectiveness.